Department of General Surgery, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
J Cachexia Sarcopenia Muscle. 2023 Dec;14(6):2602-2612. doi: 10.1002/jcsm.13334. Epub 2023 Sep 21.
Patients with decompensated cirrhosis (DC) are prone to skeletal muscle loss, namely, sarcopenia, before liver transplantation (LT). While sarcopenia is reportedly associated with adverse outcomes after LT, these findings are limited owing to mixed diseases and retrospective data. We investigated the association between sarcopenia and 1-year overall survival (OS) in patients with DC after LT and established and validated a prediction model for postoperative OS based on sarcopenia.
Overall, 222 consecutive patients who underwent LT at our centre were registered between September 2020 and June 2022. Third lumbar spine skeletal muscle mass index was measured using computed tomography. Patients were divided into sarcopenia and non-sarcopenia groups according to the skeletal muscle mass index, and baseline data and postoperative outcomes were collected, compared and analysed. The primary outcome was the 1-year OS after LT. We established a dynamic nomogram of the OS predictive model.
We included 177 DC patients [mean (standard deviation) age, 50.2 ± 9.3 years; 52 women (29.4%)]; 73 (41.2%) had sarcopenia. The mean (standard deviation) body mass index was 22.6 ± 4.5 kg/m , 28 (15.8%) patients had weight loss ≥5% within 6 months before admission, and the mean (standard deviation) model for end-stage liver disease (MELD) score was 18.4 ± 7.9. Patients with sarcopenia had a longer duration of intensive care unit stay (4.1 ± 2.2 vs. 3.1 ± 1.1 days, P = 0.008), higher rate of major complications (45.2% vs. 22.1%, P = 0.001) and higher postoperative mortality (15.1% vs. 2.9%, P = 0.003) than those without sarcopenia. The median 1-year OS after surgery was shorter in patients with sarcopenia than in those without (P < 0.001). Sarcopenia [hazard ratio (HR), 2.54; 95% confidence interval (CI), 1.54-5.63; P = 0.022], weight loss ≥5% (HR, 2.46; 95% CI, 1.39-5.09; P = 0.015) and MELD score (HR, 1.05; 95% CI, 1.01-1.09; P = 0.009) were independent risk factors associated with 1-year OS. The area under the curve of the established dynamic nomogram was 0.774, the calibration curve showed good consistency, and analysis of the decision curve showed more clinical benefits than the MELD score alone. High-risk patients (>102.9 points calculated using the nomogram) had a significantly reduced survival rate.
Sarcopenia is associated with adverse outcomes after LT in patients with DC. High-risk patients should be classified by dynamic nomogram upon admission.
在接受肝移植 (LT) 之前,失代偿性肝硬化 (DC) 患者容易出现骨骼肌丢失,即肌少症。虽然肌少症与 LT 后不良结局相关,但由于混合疾病和回顾性数据,这些发现受到限制。我们研究了肌少症与 DC 患者 LT 后 1 年总生存率 (OS) 的关系,并建立和验证了基于肌少症的术后 OS 预测模型。
我们共登记了 2020 年 9 月至 2022 年 6 月期间在我们中心接受 LT 的 222 例连续患者。使用计算机断层扫描测量第三腰椎脊柱骨骼肌质量指数。根据骨骼肌质量指数将患者分为肌少症组和非肌少症组,并收集、比较和分析基线数据和术后结果。主要结局是 LT 后 1 年 OS。我们建立了 OS 预测模型的动态列线图。
我们纳入了 177 例 DC 患者[平均(标准差)年龄 50.2±9.3 岁;女性 52 例(29.4%)];73 例(41.2%)存在肌少症。平均(标准差)体重指数为 22.6±4.5kg/m ,28 例(15.8%)患者在入院前 6 个月内体重减轻≥5%,平均(标准差)终末期肝病模型(MELD)评分为 18.4±7.9。肌少症患者 ICU 停留时间更长(4.1±2.2 天 vs. 3.1±1.1 天,P=0.008),主要并发症发生率更高(45.2% vs. 22.1%,P=0.001),术后死亡率更高(15.1% vs. 2.9%,P=0.003)。与无肌少症患者相比,肌少症患者术后 1 年 OS 更短(P<0.001)。肌少症(风险比[HR],2.54;95%置信区间[CI],1.54-5.63;P=0.022)、体重减轻≥5%(HR,2.46;95% CI,1.39-5.09;P=0.015)和 MELD 评分(HR,1.05;95% CI,1.01-1.09;P=0.009)是与 1 年 OS 相关的独立危险因素。建立的动态列线图的曲线下面积为 0.774,校准曲线显示出良好的一致性,决策曲线分析显示与单独使用 MELD 评分相比具有更多的临床获益。高风险患者(使用列线图计算>102.9 分)的生存率显著降低。
肌少症与 DC 患者 LT 后不良结局相关。高危患者应在入院时通过动态列线图进行分类。